In the TME, Th1, and Th9 subsets of CD4+T-cells enhance CD8+T-cell antitumor activity through cytokines like IL-2, IFN-γ, and IL-9, correlating with improved outcomes across cancers (34, 35). This evidence concerns the gene IFNG and cancer.